Found 54 articles for: "Atopic Derm"
A Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment
October 2024 | Volume 23 | Issue 10 | Original Article | 825 | Copyright © October 2024
The skin microbiome is essential for skin barrier function because it inhibits pathogen colonization, and decreased microbiome diversity correlates with increased Staphylococcus aureus (S. aureus...
Read MoreAssessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice Experiments
October 2024 | Volume 23 | Issue 10 | Original Article | 847 | Copyright © October 2024
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin conditions, characterized by recurrent eczema with varying degrees of erythema, pruritus, xerosis, and pain. Although there a...
Read MoreA Brief Report of 13 Cases of Poppers Dermatitis
October 2024 | Volume 23 | Issue 10 | Features | 899 | Copyright © October 2024
Topical Treatment of Atopic Dermatitis: An Adherence-Based Appraisal of the AAD Guidelines
October 2024 | Volume 23 | Issue 10 | Features | 897 | Copyright © October 2024
Safety and Tolerance Evaluation of a Suncare Product in Ethnically Diverse Children With Atopic Dermatitis-Prone Skin
August 2024 | Volume 23 | Issue 8 | Original Article | 669 | Copyright © August 2024
Atopic dermatitis (AD) is a common chronic inflammatory skin condition, with high prevalence in children. Sun protection is important for children with eczema and AD-prone skin, yet many sunscree...
Read MoreImage Analysis of Xerosis and Atopic Dermatitis Following Prebiotic Skincare Regimen in Ethnically Diverse Patients
July 2024 | Volume 23 | Issue 7 | Original Article | 557 | Copyright © July 2024
Read MoreMycosis Fungoides Palmaris et Plantaris Mimicking "Dyshidrotic Eczema": A Case Report
July 2024 | Volume 23 | Issue 7 | Case Reports | 569 | Copyright © July 2024
Mycosis fungoides palmaris et plantaris (MFPP) is a rare variant of mycosis fungoides (MF), a type of cutaneous T-cell lymphoma. MFPP primarily affects the palms and soles of the feet and is ofte...
Read MoreAnalysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients
April 2024 | Volume 23 | Issue 4 | Editorials | e121 | Copyright © April 2024
Reddit is a popular social media website that is increasingly being used as a source of health information and discussion, especially among the younger population. We analyzed the subreddit "ecze...
Read MoreAttenuation of Atopic Dermatitis in Newborns, Infants, and Children With Prescription Treatment and Ceramide-Containing Skin Care: A Systematic Literature Review and Consensus
March 2024 | Volume 23 | Issue 3 | Original Article | 152 | Copyright © March 2024
Background: Atopic dermatitis (AD) typically starts in infancy and early childhood. The chronic skin disorder is associated with recurrent flares, pruritus, and genetic predispos...
Read MoreTargeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis
February 2024 | Volume 23 | Issue 2 | Original Article | 23 | Copyright © February 2024
Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay o...
Read MoreAtopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
February 2024 | Volume 23 | Issue 2 | Case Reports | 97 | Copyright © February 2024
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A...
Read MoreTopical Moisturizer Meaningfully Reduces Disease Severity in Atopic Patients With Xerosis
December 2023 | Volume 22 | Issue 12 | Editorials | e51 | Copyright © December 2023
Background: Repairing the epidermal barrier is critically important in atopic dermatitis (AD), but the effect of moisturizer on quality of life (QOL) is not well characterized.&n...
Read MoreSelection of Nemolizumab Clinical Dosage for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical tria...
Read MoreParticipant Satisfaction of a Community-based Telehealth Clinic for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Editorials | 1066 | Copyright © October 2023
Atopic dermatitis (AD), a chronic, relapsing inflammatory disease that affects more than 30 million children and adults in the US, disproportionally impacts African American (AA) and Hispanic children...
Read MoreAnt Venom-Based Ceramide Therapy Is Effective Against Atopic Dermatitis In Vivo
October 2023 | Volume 22 | Issue 10 | Original Article | 1001 | Copyright © October 2023
Background: Atopic dermatitis (AD) is a common skin condition with relatively few therapeutic alternatives. These include corticosteroids, which address inflammation but not superinfe...
Read MoreCross-Sectional Study of Psoriasis, Atopic Dermatitis, Rosacea, and Alopecia Areata Suggests Association With Cardiovascular Diseases
June 2023 | Volume 22 | Issue 6 | Original Article | 576 | Copyright © June 2023
Background: A growing body of evidence suggests that several inflammatory skin diseases (ISDs) are associated with systemic inflammation and cardiovascular disease (CVDs)....
Read MoreBurden, Control, and Treatment of Moderate to Severe Atopic Dermatitis in 2021: A United States Patient Survey Study
February 2023 | Volume 22 | Issue 2 | Original Article | 119 | Copyright © February 2023
Background: Recent data on unmet needs in the treatment of moderate to severe atopic dermatitis (AD) in the US are not available.
Objective: To describe disease...
Read MoreA Qualitative Study on Dupilumab's Impact on Atopic Dermatitis Among Adolescent and Adult Patients
February 2023 | Volume 22 | Issue 2 | Original Article | 148 | Copyright © February 2023
Background: Atopic dermatitis (AD) is the most common inflammatory skin disease and dupilumab is US Food and Drug Administration-approved in both adult and pediatric AD patients.
Read MoreThe Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
February 2023 | Volume 22 | Issue 2 | Original Article | 139 | Copyright © February 2023
Background: Patients with atopic dermatitis (AD) need safe and effective topical treatments.
Objective: To assess safety and efficacy of roflumilast cream in pa...
Read MoreAtopic Dermatitis Polypharmacy and Out-Of-Pocket Healthcare Expenses
February 2023 | Volume 22 | Issue 2 | Original Article | 154 | Copyright © February 2023
Background: Atopic dermatitis (AD) out-of-pocket (OOP) expenses are substantial and impact household finances. Prescription polypharmacy and its association with OOP expenses in AD is...
Read More© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
